Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters











Publication year range
1.
Curr Genet ; 65(1): 193-200, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29916047

ABSTRACT

The objective of this paper is to develop a computational model of the fission yeast (Schizosaccharomyces pombe) cell cycle using agent-based modeling (ABM), to study the sequence of states of the proteins and time of the cell cycle phases, under the action of proteins that regulate its cell cycle. The model relies only on the conceptual model of the yeast cell cycle regulatory network, where each protein has been represented as an agent with a property called activity that represents its biological function and a stochastic Brownian movement. The results indicate that the simulated phase time did have similar results in comparison with other models using mathematical approaches. Similarly, the correct sequence of states was achieved, and the model was run under different initial states to understand its emergent behaviors. The cell reached the G1 stationary state 94% of the times when running the model under biological initial conditions and 87% of the times when running the model through all the different combinations of initial states. Such results imply that the cell was capable to fix toward the biological expected phenomena. These results show that ABM is a suitable technique to study protein-protein interactions without using, often unavailable, kinetic parameters, or differential equations. This model sets as a base for further studies that involve the cell cycle of the fission yeast, with a special attention to studies and development of drug treatments for specific types of cancer.


Subject(s)
G1 Phase/physiology , Models, Biological , Schizosaccharomyces pombe Proteins/physiology , Schizosaccharomyces/physiology
2.
Pharm Biol ; 55(1): 1899-1908, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28644062

ABSTRACT

CONTEXT: 4-Nerolidylcatechol (4-NRC) has showed antitumor potential through apoptosis. However, its apoptotic mechanisms are still unclear, especially in leukemic cells. OBJECTIVES: To evaluate the cytotoxic potential of 4-NRC and its cell death pathways in p53-null K562 leukemic cells. MATERIALS AND METHODS: Cytotoxicity of 4-NRC (4.17-534.5 µM) over 24 h of exposure was evaluated by MTT assay. 4-NRC-induced apoptosis in K562 cells was investigated by phosphatidylserine (PS) externalization, cell cycle, sub-G1, mitochondrial evaluation, cytochrome c, cyclin D1 and intracellular reactive oxygen species (ROS) levels, and caspase activity analysis. RESULTS: IC50 values obtained were 11.40, 27.31, 15.93 and 15.70 µM for lymphocytes, K562, HL-60 and Jurkat cells, respectively. In K562 cells, 4-NRC (27 µM) promoted apoptosis as verified by cellular morphological changes, a significant increase in PS externalization and sub-G1 cells. Moreover, it significantly arrested the cells at the G0/G1 phase due to a reduction in cyclin D1 expression. These effects of 4-NRC also significantly promoted a reduction in mitochondrial activity and membrane depolarization, accumulation of cytosolic cytochrome c and ROS overproduction. Additionally, it triggered an increase in caspases -3/7, -8 and -9 activities. When the cells were pretreated with N-acetyl-l-cysteine ROS scavenger, 4-NRC-induced apoptosis was partially blocked, which suggests that it exerts cytotoxicity though not exclusively through ROS-mediated mechanisms. DISCUSSION AND CONCLUSION: 4-NRC has antileukemic properties, inducing apoptosis mediated by mitochondrial-dependent mechanisms with cyclin D1 inhibition. Given that emerging treatment concepts include novel combinations of well-known agents, 4-NRC could offer a promising alternative for chemotherapeutic combinations to maximize tumour suppression.


Subject(s)
Apoptosis/physiology , Catechols/pharmacology , Cyclin D1/metabolism , G1 Phase/physiology , Mitochondria/metabolism , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Cyclin D1/antagonists & inhibitors , Dose-Response Relationship, Drug , G1 Phase/drug effects , HL-60 Cells , Humans , Jurkat Cells , K562 Cells , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Mitochondria/drug effects
3.
Dental press j. orthod. (Impr.) ; 20(1): 45-51, Jan-Feb/2015. tab, graf
Article in English | LILACS | ID: lil-741446

ABSTRACT

INTRODUCTION: The consensus about the relationship between TMD and orthodontic treatment has gone from a cause and effect association between TMD and orthodontic treatment to the idea that there is no reliable evidence supporting this statement. OBJECTIVE: To assess the beliefs, despite scientific evidence, of Brazilian orthodontists about the relationship between TMD and orthodontic treatment with regards to treatment, prevention and etiology of TMD. METHODS: A survey about the relationship between TMD and orthodontic treatment was prepared and sent to Brazilian orthodontists by e-mail and social networks. Answers were treated by means of descriptive statistics and strong associations between variables were assessed by qui-square test. RESULTS: The majority of orthodontists believe that orthodontic treatment not only is not the best treatment option for TMD, but also is not able to prevent TMD. Nevertheless, the majority of orthodontists believe that orthodontic treatment can cause TMD symptoms. CONCLUSION: This study suggests that orthodontists' beliefs about the relationship between orthodontic treatment and TMD are in accordance with scientific evidence only when referring to treatment and prevention of TMD. The majority of orthodontists believe that, despite scientific evidence, orthodontic treatment can cause TMD. .


INTRODUÇÃO: o consenso sobre a relação entre DTM e tratamento ortodôntico foi de uma associação de causa e efeito à ideia de que não há evidências confiáveis que suportem essa afirmação. OBJETIVO: avaliar as crenças, sem considerar as evidências, de ortodontistas brasileiros sobre a relação entre DTM e tratamento ortodôntico com relação ao tratamento, prevenção e etiologia da DTM. MÉTODOS: um questionário sobre a relação entre DTM e tratamento ortodôntico foi preparado e enviado a ortodontistas brasileiros por meio de e-mail e mídias sociais. As respostas foram analisadas por estatística descritiva, e fortes associações entre as variáveis foram verificadas pelo teste χ2. RESULTADOS: a maioria dos ortodontistas acredita que o tratamento ortodôntico não é o melhor tratamento para DTM. Além disso, acreditam que não é a melhor forma para sua prevenção. Também, a maioria dos ortodontistas acredita que o tratamento ortodôntico pode causar sintomas de DTM. CONCLUSÃO: este estudo sugere que as crenças dos ortodontistas sobre a relação entre tratamento ortodôntico e DTM estão de acordo com as evidências científicas apenas quando se trata do tratamento e da prevenção de DTM. A maioria dos ortodontistas acredita que, apesar das evidências científicas, o tratamento ortodôntico pode causar DTM. .


Subject(s)
Humans , Cell Cycle Proteins/metabolism , DNA Replication/genetics , Forkhead Transcription Factors/metabolism , G1 Phase/physiology , Gene Expression Regulation/genetics , Protein Serine-Threonine Kinases/metabolism , Replication Origin/genetics , Signal Transduction/genetics , Blotting, Western , Cell Fractionation , Cell Line , Cell Cycle Proteins/genetics , /metabolism , DNA Primers/genetics , Fluorescent Antibody Technique , Forkhead Transcription Factors/genetics , Immunoblotting , Immunoprecipitation , Intercellular Signaling Peptides and Proteins/metabolism , Protein Serine-Threonine Kinases/genetics , Proto-Oncogene Proteins c-myc/metabolism , Reverse Transcriptase Polymerase Chain Reaction , RNA Interference
4.
Biol Res ; 47: 64, 2014 Nov 25.
Article in English | MEDLINE | ID: mdl-25723815

ABSTRACT

BACKGROUND: Interactions between genes and their products give rise to complex circuits known as gene regulatory networks (GRN) that enable cells to process information and respond to external stimuli. Several important processes for life, depend of an accurate and context-specific regulation of gene expression, such as the cell cycle, which can be analyzed through its GRN, where deregulation can lead to cancer in animals or a directed regulation could be applied for biotechnological processes using yeast. An approach to study the robustness of GRN is through the neutral space. In this paper, we explore the neutral space of a Schizosaccharomyces pombe (fission yeast) cell cycle network through an evolution strategy to generate a neutral graph, composed of Boolean regulatory networks that share the same state sequences of the fission yeast cell cycle. RESULTS: Through simulations it was found that in the generated neutral graph, the functional networks that are not in the wildtype connected component have in general a Hamming distance more than 3 with the wildtype, and more than 10 between the other disconnected functional networks. Significant differences were found between the functional networks in the connected component of the wildtype network and the rest of the network, not only at a topological level, but also at the state space level, where significant differences in the distribution of the basin of attraction for the G1 fixed point was found for deterministic updating schemes. CONCLUSIONS: In general, functional networks in the wildtype network connected component, can mutate up to no more than 3 times, then they reach a point of no return where the networks leave the connected component of the wildtype. The proposed method to construct a neutral graph is general and can be used to explore the neutral space of other biologically interesting networks, and also formulate new biological hypotheses studying the functional networks in the wildtype network connected component.


Subject(s)
Cell Cycle/physiology , Cyclin-Dependent Kinases/metabolism , Gene Regulatory Networks/physiology , Models, Biological , Schizosaccharomyces/physiology , Cell Cycle Proteins/metabolism , Computational Biology , Computer Graphics , Computer Simulation , G1 Phase/physiology , Neural Networks, Computer , Schizosaccharomyces/genetics
5.
Biol. Res ; 47: 1-12, 2014. ilus, graf, tab
Article in English | LILACS | ID: biblio-950760

ABSTRACT

BACKGROUND: Interactions between genes and their products give rise to complex circuits known as gene regulatory networks (GRN) that enable cells to process information and respond to external stimuli. Several important processes for life, depend of an accurate and context-specific regulation of gene expression, such as the cell cycle, which can be analyzed through its GRN, where deregulation can lead to cancer in animals or a directed regulation could be applied for biotechnological processes using yeast. An approach to study the robustness of GRN is through the neutral space. In this paper, we explore the neutral space of a Schizosaccharomyces pombe (fission yeast) cell cycle network through an evolution strategy to generate a neutral graph, composed of Boolean regulatory networks that share the same state sequences of the fission yeast cell cycle. RESULTS: Through simulations it was found that in the generated neutral graph, the functional networks that are not in the wildtype connected component have in general a Hamming distance more than 3 with the wildtype, and more than 10 between the other disconnected functional networks. Significant differences were found between the functional networks in the connected component of the wildtype network and the rest of the network, not only at a topological level, but also at the state space level, where significant differences in the distribution of the basin of attraction for the G1 fixed point was found for deterministic updating schemes. CONCLUSIONS: In general, functional networks in the wildtype network connected component, can mutate up to no more than 3 times, then they reach a point of no return where the networks leave the connected component of the wildtype. The proposed method to construct a neutral graph is general and can be used to explore the neutral space of other biologically interesting networks, and also formulate new biological hypotheses studying the functional networks in the wildtype network connected component.


Subject(s)
Schizosaccharomyces/physiology , Cell Cycle/physiology , Cyclin-Dependent Kinases/metabolism , Gene Regulatory Networks/physiology , Models, Biological , Schizosaccharomyces/genetics , Computer Graphics , Computer Simulation , G1 Phase/physiology , Neural Networks, Computer , Cell Cycle Proteins/metabolism , Computational Biology
6.
Biochim Biophys Acta ; 1813(10): 1749-57, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21703311

ABSTRACT

Parathyroid hormone (PTH) functions as a major mediator of bone remodeling and as an essential regulator of calcium homeostasis. In this study, we investigated the role of PTH in the regulation of the cell cycle in human colon adenocarcinoma Caco-2 cells. Flow cytometry analysis revealed that PTH (10(-8)M, 12-24h) treatment increases the number of cells in the G0/G1 phase and diminishes the number in both phases S and G2/M. In addition, analysis by Western blot showed that the hormone increases the expression of the inhibitory protein p27Kip1 and diminishes the expression of cyclin D1, cyclin D3 and CDK6. However, the amounts of CDK4, p21Cip1, p15INK4B and p16INK4A were not different in the absence or presence of PTH. Inhibitors of PKC (Ro-318220, bisindolylmaleimide and chelerythine), but not JNK (SP600125) and PP2A (okadaic acid and calyculin A), reversed PTH response in Caco-2 cells. Taken together, our results suggest that PTH induces G0/G1 phase arrest of Caco-2 intestinal cells and changes the expression of proteins involved in cell cycle regulation via the PKC signaling pathway.


Subject(s)
Adenocarcinoma/pathology , Cell Cycle/drug effects , Colonic Neoplasms/pathology , Parathyroid Hormone/pharmacology , Adenocarcinoma/metabolism , Anthracenes/pharmacology , Antineoplastic Agents/pharmacology , Benzophenanthridines/pharmacology , Caco-2 Cells , Cell Cycle/physiology , Colonic Neoplasms/metabolism , Cyclin-Dependent Kinases/metabolism , Drug Evaluation, Preclinical , G1 Phase/drug effects , G1 Phase/physiology , Humans , Indoles/pharmacology , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , JNK Mitogen-Activated Protein Kinases/metabolism , JNK Mitogen-Activated Protein Kinases/physiology , Parathyroid Hormone/physiology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Protein Kinase C/physiology , Protein Kinase Inhibitors/pharmacology , Signal Transduction/drug effects
7.
Neurosci Bull ; 27(3): 185-96, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21614101

ABSTRACT

Although the cell cycle machinery is essentially linked to cellular proliferation, recent findings suggest that neuronal cell death is frequently concurrent with the aberrant expression of cell cycle proteins in post-mitotic neurons. The present work reviews the evidence of cell cycle reentry and expression of cell cycle-associated proteins as a complex response of neurons to insults in the adult brain but also as a mechanism underlying brain plasticity. The basic aspects of cell cycle mechanisms, as well as the evidence showing cell cycle protein expression in the injured brain, are reviewed. The discussion includes recent experimental work attempting to establish a correlation between altered brain plasticity and neuronal death, and an analysis of recent evidence on how neural cell cycle dysregulation is related to neurodegenerative diseases especially the Alzheimer's disease. Understanding the mechanisms that control reexpression of proteins required for cell cycle progression which is involved in brain remodeling, may shed new light into the mechanisms involved in neuronal demise under diverse pathological circumstances. This would provide valuable clues about the possible therapeutic targets, leading to potential treatment of presently challenging neurodegenerative diseases.


Subject(s)
Cell Cycle Proteins/physiology , G1 Phase/physiology , Nerve Degeneration/pathology , Neurodegenerative Diseases/pathology , Neuronal Plasticity/physiology , Neurons/cytology , Animals , Brain Injuries/pathology , Brain Injuries/physiopathology , Cell Cycle Proteins/classification , Humans , Nerve Degeneration/physiopathology , Neurodegenerative Diseases/physiopathology , Neurons/physiology
8.
J Cell Physiol ; 221(3): 560-71, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19739101

ABSTRACT

Bone formation and osteoblast differentiation require the functional expression of the Runx2/Cbfbeta heterodimeric transcription factor complex. Runx2 is also a suppressor of proliferation in osteoblasts by attenuating cell cycle progression in G(1). Runx2 levels are modulated during the cell cycle, which are maximal in G(1) and minimal beyond the G(1)/S phase transition (S, G(2), and M phases). It is not known whether Cbfbeta gene expression is cell cycle controlled in preosteoblasts nor how Runx2 or Cbfbeta are regulated during the cell cycle in bone cancer cells. We investigated Runx2 and Cbfbeta gene expression during cell cycle progression in MC3T3-E1 osteoblasts, as well as ROS17/2.8 and SaOS-2 osteosarcoma cells. Runx2 protein levels are reduced as expected in MC3T3-E1 cells arrested in late G(1) (by mimosine) or M phase (by nocodazole), but not in cell cycle arrested osteosarcoma cells. Cbfbeta protein levels are cell cycle independent in both osteoblasts and osteosarcoma cells. In synchronized MC3T3-E1 osteoblasts progressing from late G1 or mitosis, Runx2 levels but not Cbfbeta levels are cell cycle regulated. However, both factors are constitutively elevated throughout the cell cycle in osteosarcoma cells. Proteasome inhibition by MG132 stabilizes Runx2 protein levels in late G(1) and S in MC3T3-E1 cells, but not in ROS17/2.8 and SaOS-2 osteosarcoma cells. Thus, proteasomal degradation of Runx2 is deregulated in osteosarcoma cells. We propose that cell cycle control of Runx2 gene expression is impaired in osteosarcomas and that this deregulation may contribute to the pathogenesis of osteosarcoma.


Subject(s)
Cell Cycle/physiology , Core Binding Factor Alpha 1 Subunit/metabolism , Core Binding Factor beta Subunit/metabolism , Gene Expression Regulation, Neoplastic/physiology , Osteosarcoma/metabolism , Animals , Cell Line , Cell Line, Tumor , Core Binding Factor Alpha 1 Subunit/genetics , Core Binding Factor beta Subunit/genetics , Cysteine Proteinase Inhibitors , G1 Phase/physiology , Gene Expression/genetics , Humans , Leupeptins/pharmacology , Mice , Mitosis/physiology , Osteoblasts/cytology , Osteoblasts/metabolism , Osteosarcoma/pathology , Proteasome Endopeptidase Complex/metabolism , Proteasome Inhibitors , Rats , Ubiquitination/drug effects
9.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;42(6): 523-530, June 2009. ilus, tab
Article in English | LILACS | ID: lil-512760

ABSTRACT

Protein energy malnutrition (PEM) is a syndrome that often results in immunodeficiency coupled with pancytopenia. Hemopoietic tissue requires a high nutrient supply and the proliferation, differentiation and maturation of cells occur in a constant and balanced manner, sensitive to the demands of specific cell lineages and dependent on the stem cell population. In the present study, we evaluated the effect of PEM on some aspects of hemopoiesis, analyzing the cell cycle of bone marrow cells and the percentage of progenitor cells in the bone marrow. Two-month-old male Swiss mice (N = 7-9 per group) were submitted to PEM with a low-protein diet (4 percent) or were fed a control diet (20 percent protein) ad libitum. When the experimental group had lost about 20 percent of their original body weight after 14 days, we collected blood and bone marrow cells to determine the percentage of progenitor cells and the number of cells in each phase of the cell cycle. Animals of both groups were stimulated with 5-fluorouracil. Blood analysis, bone marrow cell composition and cell cycle evaluation was performed after 10 days. Malnourished animals presented anemia, reticulocytopenia and leukopenia. Their bone marrow was hypocellular and depleted of progenitor cells. Malnourished animals also presented more cells than normal in phases G0 and G1 of the cell cycle. Thus, we conclude that PEM leads to the depletion of progenitor hemopoietic populations and changes in cellular development. We suggest that these changes are some of the primary causes of pancytopenia in cases of PEM.


Subject(s)
Animals , Male , Mice , Bone Marrow Cells/physiology , Cell Proliferation , Resting Phase, Cell Cycle/physiology , G1 Phase/physiology , Hematopoietic Stem Cells/physiology , Protein-Energy Malnutrition/physiopathology , Colony-Forming Units Assay , Cell Cycle/physiology , Flow Cytometry , Fluorouracil , Protein-Energy Malnutrition/blood
10.
Braz J Med Biol Res ; 42(6): 523-30, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19448901

ABSTRACT

Protein energy malnutrition (PEM) is a syndrome that often results in immunodeficiency coupled with pancytopenia. Hemopoietic tissue requires a high nutrient supply and the proliferation, differentiation and maturation of cells occur in a constant and balanced manner, sensitive to the demands of specific cell lineages and dependent on the stem cell population. In the present study, we evaluated the effect of PEM on some aspects of hemopoiesis, analyzing the cell cycle of bone marrow cells and the percentage of progenitor cells in the bone marrow. Two-month-old male Swiss mice (N = 7-9 per group) were submitted to PEM with a low-protein diet (4%) or were fed a control diet (20% protein) ad libitum. When the experimental group had lost about 20% of their original body weight after 14 days, we collected blood and bone marrow cells to determine the percentage of progenitor cells and the number of cells in each phase of the cell cycle. Animals of both groups were stimulated with 5-fluorouracil. Blood analysis, bone marrow cell composition and cell cycle evaluation was performed after 10 days. Malnourished animals presented anemia, reticulocytopenia and leukopenia. Their bone marrow was hypocellular and depleted of progenitor cells. Malnourished animals also presented more cells than normal in phases G0 and G1 of the cell cycle. Thus, we conclude that PEM leads to the depletion of progenitor hemopoietic populations and changes in cellular development. We suggest that these changes are some of the primary causes of pancytopenia in cases of PEM.


Subject(s)
Bone Marrow Cells/physiology , Cell Proliferation , G1 Phase/physiology , Hematopoietic Stem Cells/physiology , Protein-Energy Malnutrition/physiopathology , Resting Phase, Cell Cycle/physiology , Animals , Cell Cycle/physiology , Colony-Forming Units Assay , Flow Cytometry , Fluorouracil , Male , Mice , Protein-Energy Malnutrition/blood
11.
Biochemistry ; 42(7): 2116-21, 2003 Feb 25.
Article in English | MEDLINE | ID: mdl-12590600

ABSTRACT

Arginine vasopressin (AVP) is a nonapeptide long known as an endocrine and paracrine regulator of important systemic functions, namely, vasoconstriction, gluconeogenesis, corticosteroidogenesis, and excretion of water and urea. Here we report, for the first time, that AVP specifically inhibits expression of the cyclin D1 gene, leading to cell cycle blockage and halting cell proliferation. In G0/G1-arrested mouse Y1 adrenocortical tumor cells, maintained in serum-free medium (SFM), AVP mimics FGF2, promoting rapid ERK1/2 activation (5 min) followed by c-Fos protein induction (2 h). PKC inhibitor Go6983 and PI3K inhibitors wortmannin and LY294002 all inhibit ERK1/2 activation by AVP, but not by FGF2. Thus, AVP and FGF2 concur to activate ERK1/2 by different regulatory pathways. However, AVP is not a mitogenic factor for Y1 cells. On the contrary, AVP strongly antagonizes FGF2 late induction (2-5 h) of the cyclin D1 gene, down-regulating both cyclin D1 mRNA and protein. AVP inhibition of cyclin D1 expression is sufficient to block G1 phase progression and cell entry into the S phase, monitored by BrdU nuclear labeling. In addition, AVP completely inhibits proliferation of Y1 cells in 10% fetal calf serum (10% FCS) medium. On the other hand, ectopic expression of the cyclin D1 protein renders Y1 cells resistant to AVP for both entry into the S phase in SFM and continuous proliferation in 10% FCS medium. In conclusion, inhibition of cyclin D1 expression by AVP is an efficient mechanism of cell cycle blockage and consequent proliferation inhibition in Y1 adrenocortical cells.


Subject(s)
Arginine Vasopressin/physiology , Cell Cycle/physiology , Cyclin D1/antagonists & inhibitors , Cyclin D1/biosynthesis , Gene Expression Regulation/physiology , Growth Inhibitors/physiology , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/pathology , Adrenal Cortex Neoplasms/enzymology , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/pathology , Animals , Arginine Vasopressin/pharmacology , Cell Cycle/drug effects , Clone Cells , Culture Media, Conditioned , Cyclin D1/genetics , Drug Resistance, Neoplasm , Enzyme Activators/pharmacology , Fibroblast Growth Factor 2/pharmacology , G1 Phase/drug effects , G1 Phase/physiology , Gene Expression Regulation/drug effects , Growth Inhibitors/pharmacology , Mice , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Molecular Mimicry , Phosphatidylinositol 3-Kinases/physiology , Protein Kinase C/physiology , Resting Phase, Cell Cycle/drug effects , Resting Phase, Cell Cycle/physiology , Transfection , Tumor Cells, Cultured/enzymology
12.
Endocr Res ; 26(4): 825-32, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11196459

ABSTRACT

In G0/G1 cell cycle arrested mouse Y1 adrenocortical tumor cells ACTH39, a weak mitogen and strong anti-mitogenic agent, blocks FGF2 mitogenic activity at G1 phase, keeping untouched ERK-MAPK activation and c-Fos protein induction. Here we report two anti-mitogenic mechanisms initiated in ACTH receptors and mediated by cAMP/PKA: a) post-transcriptional down regulation of c-Myc protein; b) dephosphorylation of AKT/PKB. In Y-1 cells the activity of the Mad/Max/Myc network of transcription factors seems to be regulated by c-Myc levels. FGF2 induces c-myc gene and stabilizes c-Myc protein by a process dependent on ERK-MAPK (PD98059 sensitive), but not on PI3K (Wortmannin resistant). ACTH39, on the other hand, causes rapid decrease in c-Myc levels induced by FGF2 in wild type Y1 cells, but not in PKA-deficient Y1 clones. The ACTH inhibition of DNA synthesis stimulated by FGF2 is reversed by transient transfection and induction of the MycER chimera (fusion of c-Myc and estrogen-receptor), suggesting that c-Myc down regulation is an efficient anti-mitogenic mechanism activated by ACTH. Y1 cells display high constitutive levels of AKT/PKB, that is dependent on elevated Ras x GTP. FGF2 up regulates Ras x GTP, PI3K and AKT/PKB. ACTH antagonizes this mitogenic effect of FGF2, promoting rapid dephosphorylation of AKT/PKB.


Subject(s)
Adrenal Cortex/pathology , Adrenocorticotropic Hormone/pharmacology , Fibroblast Growth Factor 2/pharmacology , G1 Phase/physiology , Protein Serine-Threonine Kinases , Resting Phase, Cell Cycle/physiology , Signal Transduction/drug effects , Adrenal Cortex/drug effects , Animals , Down-Regulation , Mice , Phosphorylation/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-myc/metabolism , Tumor Cells, Cultured
13.
Int J Radiat Biol ; 59(6): 1371-8, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1677382

ABSTRACT

Chinese hamster ovary (CHO) cells were treated with bovine pancreatic DNase I using the method of electroporation. The enzyme induced chromosomal aberrations in a S-phase independent manner. The frequencies of polycentric chromosomes induced in the G1 phase of the cell cycle are positively correlated with the dose of DNase I. The distributions of DNase I-induced polycentric chromosomes were overdispersed.


Subject(s)
Chromosome Aberrations , Deoxyribonuclease I/pharmacology , Animals , Cell Line , Deoxyribonuclease I/administration & dosage , Dose-Response Relationship, Drug , G1 Phase/physiology , Pancreas/enzymology , S Phase/physiology
SELECTION OF CITATIONS
SEARCH DETAIL